Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Swiss pharmaceutical giant Novartis (NVS - Snapshot Report) recently presented data from two phase III studies comparing Tasigna (nilotinib) with Glivec (imatinib) for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed patients. The patients in the study were switched to Tasigna after long-term treatment with Glivec.

The company presented these data at the American Society of Hematology (ASH). Results from the two-year ENESTcmr study showed that patients who switched to Tasigna achieved a significant deeper molecular response compared to those who remained under Glivec treatment. The study also revealed that more than twice as many patients treated with Tasigna were persistent in achieving undetectable BCR-ABL compared to Glivec.

Novartis also presented data from a four-year landmark analysis from ENESTnd on Tasigna. Results from this study showed that more than thrice as many patients with Tasigna as frontline therapy achieved early molecular response compared to Glivec.

Novartis also presented efficacy and safety data from a separate four-year analysis from ENESTnd. The data showed that molecular response rates of both 4 and 4.5 were higher for Tasigna. Novartis also reported that overall survival remained same in all the groups at the end of four years, though a lesser number of deaths occurred in both the Tasigna dose (300mg and 400mg) compared to Glivec.

We note that Tasigna is already approved as a treatment of first and second line chronic myeloid leukemia (CML) and Ph+ CML in adults who are resistant or intolerant to Glivec. Novartis reported Tasigna sales of $261 million in the third quarter of 2012. In November, the company stated that it is planning additional clinical trials on Tasigna next year.

Glivec is approved for the treatment of Ph+CML and gastrointestinal stromal tumors (GIST). Glivec sales in the third quarter of 2012 were $1.2 billion.

We are encouraged by the company’s efforts to strengthen its position in the Ph+CML and CML area. With additional approvals and treatment options the company will be able to entrench its position in this crucial disease area.

Currently, we have a Neutral recommendation on Novartis. Novartis carries a Zacks #3 Rank (Hold) in the short run. Other pharma companies like Sanofi (SNY - Analyst Report), Roche (RHHBY - Analyst Report) and Bayer (BAYRY - Analyst Report) carry a Zacks #2 Rank (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%